All Videos

Focusing on JAK inhibitors, panelists consider the historical use of these agents in atopic dermatitis and their corresponding mechanisms of action.

In this week’s Pointers with Dr Portela, the 208SkinDoc reacts to Nicki Minaj’s tweets about skin care, diving into whether her advice is true or not, and if a dermatology would recommend her routine.

Experts define stages of atopic dermatitis and share insight on the conventional treatment landscape for mild to moderate and moderate to severe atopic dermatitis.

Expert perspectives on the nature of atopic dermatitis, ranging from diagnosis and pathophysiology to the clinical and social burden it places on patients.

In a follow up interview about the results from the American Academy of Facial Plastic and Reconstructive Surgery annual survey AAFPRS president Corey S. Maas, MD, sits down to talk in depth details about the outcomes.

Drs James Q. Del Rosso and Neal Bhatia explain how to manage patients who fail therapy and provide safety considerations when treating those patients.

In this week’s Pointers with Dr Portela, the 208SkinDoc reacts to an episode of Botched, which was about a patient with basal cell carcinoma (BCC), whose tanning in her younger years led to Mohs surgery.

A recent mouse model study on the efficacy of using imatinib as a treatment for Sturge Weber Syndrome has been published. In this video interview we talk with one of the investigators, Jack L. Arbiser, MD, PhD, on what the results means for future clinical trials.

Experts discuss newly approved oral JAK inhibitors for the treatment of atopic dermatitis.

In this week’s Pointers with Dr Portela, the 208SkinDoc dives into the newest attempt at blue light protecting skin care, providing a full review of the products, its ingredients, and if there is any science behind its claims.

We sit down with the experts to determine what legal and tax factors come into play when deciding on the best corporate structure for a dermatology practice.

A review of topical JAK inhibitor ruxolitinib.

In this week’s Pointers with Dr Portela, the 208SkinDoc highlights a growing issue of lasers made to look like or mimic the technology of already approved lasers but can have dangerous consequences.

James Q. Del Rosso, DO, and Neal Bhatia, MD, provide an overview of JAK inhibitors for the treatment of atopic dermatitis.

Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.

Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses the best way to tackle wrinkles with Azadeh Shirazi, MD.

A brief discussion on the unmet needs and ongoing challenges in the treatment of plaque psoriasis.

Shared insight on which factors are most important in determining second-line therapy for plaque psoriasis.

Suneel Chilukuri, MD, discusses lower eyelid rejuvenation, including avoiding complications, in his presentation at the Maui Derm for Dermatologists meeting.

Suneel Chilukuri, MD, discusses new innovations in dermatology, including hyperpigmentation, in his presentation at the Maui Derm for Dermatologists meeting.

Robert S. Kirsner, MD, PhD, discusses new and tried-and-true wound healing methods in his presentation at the Maui Derm for Dermatologists meeting.

Linda Stein Gold, MD, discusses psoriasis in 2022, in her presentation at the current Maui Derm for Dermatologists meeting.

Linda Stein Gold, MD, and Matthew Zirwas, MD, share some advice for clinicians on how to discuss JAK inhibitors with patients.

Moving on to the second patient case, panelists discuss switching therapy at treatment failure for plaque psoriasis.

Panelists share which factors they use to determine optimal therapy in the moderate to severe plaque psoriasis setting.

In this week’s Pointers with Dr Portela, the 208SkinDoc dives into a social media video that shows someone advocating for urine for hair, skin, and overall body care. See what he has to say about this suggestion.

Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.

Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.

A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.